alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
UNITED STATES DISTRICT COURT 

FOR THE DISTRICT OF COLUMBIA 

FILED 

OCT - Ii 2010 

Clerk Us D' C ". Istrict & Ourts for the Dist( t Bankruptcy 

Kareemah Bell, IC of COlumbia 

Plaintiff, 

v. 

) 

) 

) 

) 

) 

) 

) 

) 

) 

Civil Action No. 10 1710 

Metropolitan Police/Hope Shelter, 

Defendants. 

MEMORANDUM OPINION 

This matter is before the Court on plaintiff's pro se complaint and application to proceed 

in forma pauperis. The Court will grant plaintiff's application and dismiss the complaint for lack 

of subject matter jurisdiction. 

The subject matter jurisdiction of the federal district courts is limited and is set forth 

generally at 28 U.S.c. §§ 1331 and 1332. Under those statutes, federal jurisdiction is available 

only when a "federal question" is presented or the parties are of diverse citizenship and the 

amount in controversy exceeds $75,000. A party seeking relief in the district court must at least 

plead facts that bring the suit within the court's jurisdiction. See Fed. R. Civ. P. 8(a). Failure to 

plead such facts warrants dismissal of the action. See Fed. R. Civ. P. 12(h)(3). 

Plaintiff, who lists her mailing address as a Landover Hills, Maryland, residence, sues 

presumably the District of Columbia Metropolitan Police Department and D.C.-based Hope 

Shelter for an alleged assault by a homeless woman at the shelter. The complaint neither 

presents a federal question nor provides a basis for diversity jurisdiction because no amount in 

controversy is pleaded. A separate Order of dismissal accompanies this Memorandum Opinion. 

Date: __ --'---+-'-"-'u-=-_, 2010 

~/L.SN~ United States District Judge
YAN PING XU, petitioner, v. CITY OF NEW YORK, NEW YORK, et al.

No. 18-69.

Supreme Court of the United States

Oct. 1, 2018.

Petition for writ of certiorari to the United States Court of Appeals for the Second Circuit denied.
<TABLE> <S> <C>


<ARTICLE> 5
<LEGEND>
THIS  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL   INFORMATION  EXTRACTED  FROM  THE
FINANCIAL  STATEMENTS  OF QPQ  CORPORATION  FOR THE SIX MONTHS ENDED JUNE 30,
1997,  AND  IS  QUALIFIED  IN  ITS  ENTIRETY  BY  REFERENCE  TO  SUCH  FINANCIAL
STATEMENTS.
</LEGEND>
<MULTIPLIER> 1

       
<S>                                 <C>
<PERIOD-TYPE>                       6-MOS
<FISCAL-YEAR-END>                   DEC-31-1997
<PERIOD-START>                      JAN-01-1997
<PERIOD-END>                        JUN-30-1997
<CASH>                                  362,798 
<SECURITIES>                                  0 
<RECEIVABLES>                           317,172 
<ALLOWANCES>                                  0 
<INVENTORY>                                   0 
<CURRENT-ASSETS>                        709,970 
<PP&E>                                  492,115 
<DEPRECIATION>                           99,920 
<TOTAL-ASSETS>                        1,232,609 
<CURRENT-LIABILITIES>                   104,553 
<BONDS>                                       0 
<PREFERRED-MANDATORY>                         0 
<PREFERRED>                                   0 
<COMMON>                                  6,553 
<OTHER-SE>                            1,081,503 
<TOTAL-LIABILITY-AND-EQUITY>          1,232,609 
<SALES>                                 538,723 
<TOTAL-REVENUES>                        538,723 
<CGS>                                 1,070,527 
<TOTAL-COSTS>                         1,070,527 
<OTHER-EXPENSES>                        991,271 
<LOSS-PROVISION>                        429,088 
<INTEREST-EXPENSE>                       26,872 
<INCOME-PRETAX>                      (1,979,035)
<INCOME-TAX>                                  0 
<INCOME-CONTINUING>                  (1,979,035)
<DISCONTINUED>                         (617,213)
<EXTRAORDINARY>                               0 
<CHANGES>                                     0 
<NET-INCOME>                         (2,596,248)
<EPS-PRIMARY>                             (6.13)
<EPS-DILUTED>                             (6.13)
                                                 

</TABLE>
James Morris SELLERS, petitioner, v. UNITED STATES.

No. 18-5520.

Supreme Court of the United States

Oct. 1, 2018.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.
Tommy Earl BOONE, Jr., petitioner, v. TEXAS.

No. 18-8197.

Supreme Court of the United States

April 29, 2019.

Motion of petitioner for leave to proceed *in forma pauperis* denied, and petition for writ of certiorari to the Court of Criminal Appeals of Texas dismissed. See Rule 39.8.
```
 
 
VIX FUTURES - CBOE FUTURES EXCHANGE                                  Code-1170E1
FUTURES ONLY POSITIONS AS OF 05/29/12                         |
--------------------------------------------------------------| NONREPORTABLE
      NON-COMMERCIAL      |   COMMERCIAL    |      TOTAL      |   POSITIONS
--------------------------|-----------------|-----------------|-----------------
  LONG  | SHORT  |SPREADS |  LONG  | SHORT  |  LONG  | SHORT  |  LONG  | SHORT
--------------------------------------------------------------------------------
($1000 X INDEX)                                      OPEN INTEREST:      272,588
COMMITMENTS
  62,303   85,934   36,635  152,502  129,581  251,440  252,150   21,148   20,438

CHANGES FROM 05/22/12 (CHANGE IN OPEN INTEREST:    -15,047)
  -8,584   -9,415     -510   -7,483   -7,962  -16,577  -17,887    1,530    2,840

PERCENT OF OPEN INTEREST FOR EACH CATEGORY OF TRADERS
    22.9     31.5     13.4     55.9     47.5     92.2     92.5      7.8      7.5

NUMBER OF TRADERS IN EACH CATEGORY (TOTAL TRADERS:      128)
      33       49       51       32       37       97      113
```

----

Updated June 5, 2012
**Exhibit 99.0**

 

**CERTIFICATIONSOF**

#### **CHIEFEXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER**

**PURSUANTTO 18 U.S.C. SECTION 1350,**

**ASADOPTED PURSUANT TO**

**SECTION906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connectionwith the Quarterly Report of Titan Pharmaceuticals, Inc. (the “Company”) onForm 10-Q for the period ended March 31, 2003 as filed with the Securities andExchange Commission on the date hereof (the “Report”), I, Louis R. Bucalo,M.D., Chairman, President and Chief Executive Officer of the Company, certify,pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of theSarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

(1) The Report fully complies with the requirements of section 13(a) or15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in allmaterial respects, the financial condition and result of operations of theCompany for the period certified.

 

Signed at theCity of South San Francisco, in the State of California, this 15thday of May, 2003.

 

 
|   | /s/ Louis R. Bucalo   |   |
|--------|-----------------------|--------|
|   | Louis R. Bucalo, M.D. |

 

 

In connectionwith the Quarterly Report of Titan Pharmaceuticals, Inc. (the “Company”) onForm 10-Q for the period ended March 31, 2003 as filed with the Securities andExchange Commission on the date hereof (the “Report”), I, Robert E. Farrell,J.D., Executive Vice President and Chief Financial Officer of the Company,certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

(1) The Report fully complies with the requirements of section 13(a) or15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in allmaterial respects, the financial condition and result of operations of theCompany for the period certified.

 

 

Signed at the City of South San Francisco, in the State of California,this 15th day of May, 2003.

 

 
|   | /s/ Robert E. Farrell   |   |
|--------|-------------------------|--------|
|   | Robert E. Farrell, J.D. |

 

----
<PAGE>

                                                                   EXHIBIT 10.21





Mr. Georges Antoun
2716 Sylvan Way
McKinney
TX 75070

Dear Georges:


     It was a pleasure meeting you today. I believe you will be a great addition
to the Redback team.

     We would like to offer you the position of Sr VP of Business Development,
reporting to the CEO. Your starting salary will be $300K and you will be
eligible for a $300K bonus. For this year the bonus is guaranteed and will be
prorated i.e. assuming you start on September 4 you will receive a bonus based
on the number of days between September 4 and December 31. For subsequent years
your bonus will based on achieving goals set for you by the CEO.

     In addition you will receive a $250K sign on bonus. If you should leave the
company within one year you will have to repay a portion of this bonus. This
will be an after tax reimbursement and will be computed based on the amount of
time you have spent with the company. In other words if you leave at the end of
nine months, 25% of the $250K should go back to the company, we will compute
the amount on an after tax (50%) basis.

     We will also offer you an option for 1,000,000 shares of Redback common
stock, subject to our normal option agreement: 1 year cliff, 4 year vesting, and
the approval of the Board of Directors. The unvested shares will vest fully if
there is a change of control and your responsibilities are diminished. The
option will be priced on your first day of work at Redback.

     I hope you will accept this offer, please sign and fax a copy of this
letter at 650-325-7288.


     Very truly yours,           Read and accepted
     Pierre R. Lamond            Georges Anton
     Chairman of the Board

     /s/ Pierre R. Lamond        /s/ Georges Anton


                                 Date:
Derek W. PELTO, petitioner, v. Julie L. JONES, Secretary Florida Department of Corrections, et al.

No. 18-5539.

Supreme Court of the United States

Oct. 1, 2018.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.